SG Americas Securities
XENE icon

SG Americas Securities’s Xenon Pharmaceuticals XENE Stock Holding History

SG Americas Securities’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$361K Sell
5,982
-3,137
-34% -$174K ﹤0.01% 2488
2026
Q1 		$530K Buy
9,119
+2,042
+29% +$94.1K ﹤0.01% 2152
2025
Q4 		$317K Buy
7,077
+149
+2% +$6.26K ﹤0.01% 2727
2025
Q3 		$278K Sell
6,928
-12,249
-64% -$431K ﹤0.01% 2541
2025
Q2 		$600K Buy
19,177
+10,522
+122% +$343K ﹤0.01% 1537
2025
Q1 		$290K Sell
8,655
-4,638
-35% -$176K ﹤0.01% 2238
2024
Q4 		$521K Buy
13,293
+5,577
+72% +$231K ﹤0.01% 1310
2024
Q3 		$304K Sell
7,716
-18,463
-71% -$744K ﹤0.01% 2139
2024
Q2 		$1.02M Buy
26,179
+5,813
+29% +$232K 0.01% 1290
2024
Q1 		$877K Buy
20,366
+1,760
+9% +$81K ﹤0.01% 1185
2023
Q4 		$857K Sell
18,606
-38,146
-67% -$1.35M 0.01% 1111
2023
Q3 		$1.94M Buy
56,752
+17,490
+45% +$654K 0.02% 754
2023
Q2 		$1.51M Buy
39,262
+13,385
+52% +$532K 0.01% 867
2023
Q1 		$926K Sell
25,877
-9,588
-27% -$354K 0.01% 1187
2022
Q4 		$1.4M Buy
35,465
+13,633
+62% +$496K 0.02% 758
2022
Q3 		$788K Sell
21,832
-621
-3% -$22.3K 0.01% 1184
2022
Q2 		$683K Buy
+22,453
New +$679K 0.01% 1670

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SG Americas Securities's XENE Position: Q2 2026 in Review

SG Americas Securities reduced its Xenon Pharmaceuticals (XENE) stake by 34% in Q2 2026, selling an estimated $174K and leaving 5,982 shares worth $361K. The position accounts for ﹤0.01% of the portfolio, ranked #2488.

SG Americas Securities first reported a position in XENE in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.94M in Q3 2023. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • SG Americas Securities held 5,982 shares of Xenon Pharmaceuticals worth $361K as of Q2 2026.
  • SG Americas Securities sold 3,137 Xenon Pharmaceuticals shares in Q2 2026, an estimated $174K.
  • Xenon Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2488 holding.
  • SG Americas Securities first reported a position in Xenon Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • SG Americas Securities's Xenon Pharmaceuticals position peaked at $1.94M in Q3 2023.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.